Chinese pharmaceutical firms listed in Hong Kong are projected to see a significant uplift in their profitability, primarily fueled by their innovative drug sales and licensing agreements. According to Tony Ren, the head of Asia Healthcare Research at Macquarie Capital, earnings from these innovative drugs are anticipated to remain robust as the sector navigates challenges such as drug pricing pressures in the domestic market. He highlighted the outlook for 2025 as particularly positive, reflecting investor confidence in the industry’s recovery and growth trajectory.

For example, Innovent Biologics, a prominent player in this sector known for its cancer treatment drug development, reported an astonishing revenue increase of approximately 45% in 2025, reaching about 11.9 billion yuan. This positive growth marks a historic milestone for the company, which was recognized for launching six new products within the last year. The company is expected to disclose its full earnings report at the end of March, providing further insights into its financial performance and the overall health of the market.

Founded in 2011, Innovent was among the pioneering companies that took advantage of new Hong Kong listing regulations in 2018, which allowed pre-revenue and loss-making drug and medical device developers to raise vital capital. This progressive approach has positioned Innovent and similar firms to be at the forefront of China's burgeoning pharmaceutical industry, further demonstrating the potential for growth amidst the challenges that local companies face.